UNASSIGNED: Relapsed @entity706 often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the @entity10412 / @entity3470 pathway in several types of @entity706 has shown preclinical and clinical efficacy providing the rationale to test this strategy in the treatment of relapsed/refractory @entity706 . We investigated in a phase II open label clinical trial the efficacy and safety of single agent @entity2239 , an inhibitor of @entity13407 , in @entity1 with relapsed/refractory @entity706 . Eligible @entity1 received oral @entity2239 10 mg daily on a 28 day-cycle schedule. The primary endpoint was to evaluate the overall response rate (ORR) and safety of single-agent @entity2239 in this @entity1 population. Fifty-five @entity1 with @entity706 were accrued. The median age was 67 years (range: 33-85) with a median of 5 prior therapies (range: 1-10). The ORR was 35% (19/55; 95%-CI: 24-48%), with complete response unconfirmed in 4% (2/55), and partial response in 31% (17/55). The ORR was 61% (14/23) in the @entity1 with FL. The median time to response was 2.3 months (range: 1.4-14.1), median duration of response of 11.5 months (95%-CI: 5.7-30.4), and a median progression-free survival of 7.2 months (95%-CI: 5.5-12.5). The most common @entity137 was hematologic with grades 3-4 @entity417 , @entity1398 , and @entity882 documented in 15% (8/55), 22% (12/55), and 33% (18/55), respectively. There were no cases of @entity1398 , and eight @entity1 discontinued therapy because of adverse events. @entity2239 monotherapy is a valid therapeutic option in the relapsed and/or refractory indolent @entity1893 @entity1 and is well tolerated. This article is protected by copyright. All rights reserved.

Efficacy of the oral @entity13407 inhibitor @entity2239 in relapsed or refractory XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'indolent lymphoma', 'indolent lymphomas'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity13407 :: ('382056(Tax:10090)', 'Gene') :: ['mTORC1'] @entity2239 :: ('MESH:C107135', 'Chemical') :: ['Everolimus', 'everolimus'] @entity3470 :: ('21977(Tax:10090)', 'Gene') :: ['mTOR'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity10412 :: ('5293', 'Gene') :: ['PI3K'] @entity1893 :: ('MESH:D008228', 'Disease') :: ['non-Hodgkin lymphoma']
@entity706 :: (MESH:D008223,Disease) :: ['indolent lymphoma']
